⌘K

Login Start Free

Home/Filings/4/0001209191-22-036037

4//SEC Filing

Fardis Maria 4

Accession 0001209191-22-036037

CIK 0001674416other

View on SEC.gov Company Profile

Filed

Jun 9, 8:00 PM ET

Accepted

Jun 10, 5:37 PM ET

Size

5.3 KB

Accession

0001209191-22-036037

Insider Transaction Report

Form 4

Period: 2022-06-09

CRISPR Therapeutics AGCRSP

Director

Transactions

Award
Stock Option (Right to Buy)
2022-06-09+24,000→ 24,000 total
Exercise: $71.70Exp: 2032-06-09→ Common Shares (24,000 underlying)

Footnotes (1)

[F1]This option was granted on June 9, 2022 with respect to 24,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

CRISPR Therapeutics AG

CIK 0001674416

Entity typeother

Related Parties

1

filerCIK 0001559231

Filing Metadata

Form type: 4
Filed: Jun 9, 8:00 PM ET
Accepted: Jun 10, 5:37 PM ET
Size: 5.3 KB

View on SEC.gov